Abstract
Due to the radiosensitivity of the lung, toxic endpoints, in the form of radiation pneumonitis and pulmonary fibrosis, are relatively frequent outcomes following radiation treatment of thoracic neoplasms. Because of the potential lethal nature of these normal tissue reactions, they not only lead to quality-of-life issues in survivors, but also are deemed dose-limiting and thereby compromise treatment. The mitigation and treatment of lung normal tissue late effects has therefore been the goal of many investigations; however, the complexity of both the organ itself and its response to injury has resulted in little success. Nonetheless, current technology allows us to propose likely targets that are either currently being researched or should be considered in future studies.
Keywords: Radiation, lung, pneumonitis, pulmonary fibrosis, pulmonary, neoplasms, bronchiole, endothelium, fibroblasts, FDA, (ROS), (SOD), Mn-SOD, (L-NAME), (iNOS), DNA damage, (SP-A), (COX-2), HMG-CoA, (MCP-1), Cytokine, (TNF), IL-1, TGF-ß, RAS, ACE
Current Drug Targets
Title: Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Volume: 11 Issue: 11
Author(s): Jacqueline P. Williams, Carl J. Johnston and Jacob N. Finkelstein
Affiliation:
Keywords: Radiation, lung, pneumonitis, pulmonary fibrosis, pulmonary, neoplasms, bronchiole, endothelium, fibroblasts, FDA, (ROS), (SOD), Mn-SOD, (L-NAME), (iNOS), DNA damage, (SP-A), (COX-2), HMG-CoA, (MCP-1), Cytokine, (TNF), IL-1, TGF-ß, RAS, ACE
Abstract: Due to the radiosensitivity of the lung, toxic endpoints, in the form of radiation pneumonitis and pulmonary fibrosis, are relatively frequent outcomes following radiation treatment of thoracic neoplasms. Because of the potential lethal nature of these normal tissue reactions, they not only lead to quality-of-life issues in survivors, but also are deemed dose-limiting and thereby compromise treatment. The mitigation and treatment of lung normal tissue late effects has therefore been the goal of many investigations; however, the complexity of both the organ itself and its response to injury has resulted in little success. Nonetheless, current technology allows us to propose likely targets that are either currently being researched or should be considered in future studies.
Export Options
About this article
Cite this article as:
P. Williams Jacqueline, J. Johnston Carl and N. Finkelstein Jacob, Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?, Current Drug Targets 2010; 11 (11) . https://dx.doi.org/10.2174/1389450111009011386
DOI https://dx.doi.org/10.2174/1389450111009011386 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Targeting of Drug Delivery Systems to Cancer
Current Drug Targets Personalized & Precision Medicine in Cancer: A Theranostic Approach
Current Radiopharmaceuticals New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry The Interactions of Anticancer Agents with Tea Catechins: Current Evidence from Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology Signal Transduction Inhibitors as Radiosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies
Current Drug Delivery Exploring the Role of Phytochemicals as Potent Natural Photosensitizers in Photodynamic Therapy
Anti-Cancer Agents in Medicinal Chemistry β -Glucans and their Applications in Cancer Therapy: Focus on human studies
Anti-Cancer Agents in Medicinal Chemistry Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Signal Transducer and Activator of Transcription 5 (STAT5), a Crucial Regulator of Immune and Cancer Cells
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Editorial (Thematic Issue: Oncoviruses and Head and Neck Cancer: An Impending Facts)
Recent Patents on Biomarkers miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Treatment Approaches in Elderly Patients with Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals A Proteomic Approach To Porcine Saliva
Current Protein & Peptide Science Therapeutic Use of Snake Venom Components: A Voyage from Ancient to Modern India
Mini-Reviews in Organic Chemistry